Siegfried, a worldwide leading CDMO, produces active pharmaceutical ingredients (APIs), intermediates and finished products from a single source. Our core competence is process development and the integration of complementary chemical and pharmaceutical capabilities in a single business model.
Report
“Despite the uncertain environment caused by the pandemic, Siegfried took a significant step in implementing its corporate strategy EVOLVE in the year under review with the acquisition of two large drug products sites from Novartis in Barcelona.”
Dr. Andreas Casutt
Chairman of the Board of Directors
Dr. Wolfgang Wienand
Chief Executive Officer
Dear Shareholders
The Siegfried Group achieved a good operating result in a demanding environment characterized by the coronavirus pandemic, and it proved capable of mastering exceptional challenges. In addition, significant progress was made within the framework of our EVOLVE strategy, which takes the company into a new dimension and will have a positive impact on the business results already in the current year.
